Gastrointestinal cancers
Adjuvant FOLFOX, anti-EGFR in RAS-WT mCRC, FOLFIRINOX, immunotherapy in MSI-H and oesophageal/gastric cancers.
- Trials
- 5
- Years
- 2004–2021
Sort
- 2021CheckMate-577Oesophageal adjuvantIn 794 patients with resected oesophageal/GEJ cancer and residual pathologic disease after neoadjuvant chemoradiation, adjuvant nivolumab for one year improved disease-free survival compared with placebo.HR 0.69Read →
- 2020KEYNOTE-177MSI-H mCRCIn 307 patients with untreated MSI-H/dMMR metastatic colorectal cancer, pembrolizumab improved progression-free survival compared with chemotherapy ± targeted agents.HR 0.6Read →
- 2011PRODIGE 4 / ACCORD 11Metastatic pancreaticIn 342 patients with metastatic pancreatic adenocarcinoma, ECOG 0–1, age ≤75, FOLFIRINOX improved overall survival compared with gemcitabine.HR 0.57Read →
- 2009CRYSTALmCRC anti-EGFRIn 1,198 patients with untreated metastatic colorectal cancer, cetuximab + FOLFIRI improved PFS in the KRAS/RAS wild-type subgroup compared with FOLFIRI alone.HR 0.7Read →
- 2004MOSAIC CoreColon adjuvantIn 2,246 patients with resected stage II/III colon cancer, adjuvant FOLFOX4 improved disease-free survival compared with 5-FU/leucovorin.HR 0.77Read →